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Abstract
Background: A genomic biomarker identifying patients likely to benefit from drotrecogin alfa (activated) (DAA)
may be clinically useful as a companion diagnostic. This trial was designed to validate biomarkers (improved
response polymorphisms (IRPs)). Each IRP (A and B) contains two single nucleotide polymorphisms that were
associated with a differential DAA treatment effect.
Methods: DAA is typically given to younger patients with greater disease severity; therefore, a well-matched control
group is critical to this multicenter, retrospective, controlled, outcome-blinded, genotype-blinded trial. Within each
center, DAA-treated patients will be matched to controls treated within 24 months of each other taking into account
age, APACHE II, cardiovascular, respiratory, renal, and hematologic dysfunction, mechanical ventilation status, medical/
surgical status, and infection site. A propensity score will estimate the probability that a patient would have received
DAA given their baseline characteristics. Two-phase data transfer will ensure unbiased selection of matched controls.
The first transfer will be for eligibility and matching data and the second transfer for outcomes and genotypic data. The
primary analysis will compare the effect of DAA in IRP+ and IRP−groups on in-hospital mortality through day 28.
Discussion: A design-based approach matching DAA-free to DAA-treated patients in a multicenter study of patients
who have severe sepsis and high risk of death will directly compare control to DAA-treated groups for mortality by
genotype. Results, which should be available in 2012, may help to identify the group of patients who would benefit
from DAA and may provide a model for future investigation of sepsis therapies.
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sepsis, Treatment selection, Sepsis, Drotrecogin alfa activated (DAA), Activated protein C, Genome wide association
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Background
There are approximately 750,000 new cases of severe sep-
sis per year in the United States (US) [1] and 300,000 in
the European Union (EU) [2]. The incidence of septic
shock is increasing [3] and mortality from severe sepsis
and septic shock is high, ranging from 30% to 60%,
respectively.
PROWESS, the first Phase III, randomized, controlled
trial of drotrecogin alfa (activated) (DAA) (recombinant
human activated protein C), demonstrated an absolute
risk reduction (ARR) of 6.1% in the 28-day mortality rate
(P=0.005) in severe sepsis [4]. The U.S. Food and Drug
Administration (FDA) approved DAA but raised concerns,
because the PROWESS protocol was amended approxi-
mately half way through the study, with modification of
eligibility criteria, study objectives, and covariates for ad-
justment of the primary endpoint [5,6]. Other trials have
not lessened the controversy about DAA. The ADDRESS
study in sepsis patients at low risk of death [7], and the
RESOLVE trial, in children with sepsis-induced cardiovas-
cular and respiratory failure [8], were both stopped for fu-
tility. Moreover, there are safety concerns, including
increased incidence of serious bleeding after DAA com-
pared to placebo (5.6% DAA; 2.0% placebo, P< 0.001) [9].
The FDA approved DAA for patients with severe sepsis
and high risk of death (e.g., APACHE II≥ 25) [10]. Market-
ing authorization in the EU was granted for patients with
severe sepsis and two or more organ failures. The EU ap-
proval was subject to annual reviews and the provision of
additional data to support efficacy and safety [11]. PROW-
ESS SHOCK, a randomized, placebo-controlled trial of
DAA in 1,696 patients with septic shock [12] showed that
28-day mortality was 26.4% and 24.2% in the DAA and
placebo arms, respectively (P=0.31), with remarkably low
rates of serious bleeding (1.2% vs. 1%). On October 25,
2011, Eli Lilly and Company withdrew DAA from the
market worldwide. For PROWESS SHOCK, the observed
pooled mortality was much lower than expected, lower
than in PROWESS, which enrolled a broader population
of severe sepsis [4]. The low mortality rates observed in
PROWESS SHOCK may be explained in part by recent
advances in the management of septic shock and in part
by the selection of lower risk patients. If DAA is to be
reintroduced clinically, an effective strategy must involve
better tools for the selection of patients who will respond
to DAA. The study design and statistical methods for this
study have been discussed with the U.S. FDA.
Background on selection of pharmacogenomic
biomarkers for current study (SGX301)
Pharmacogenomic markers identify patients predicted to
have increased efficacy or greater likelihood of adverse
effects of many drugs [13]. To screen for genomic biomar-
kers, a Genome Wide Association Study (GWAS) of the
PROWESS study was performed (unpublished data). The
GWAS used blood spot samples from 1,446 patients to
genotype approximately 1.2 million SNPs (IlluminaW
Human1M-Duo BeadChip). Findings were then tested in a
small, combined replication cohort drawn from the single-
center St. Paul’s Hospital (SPH) registry and the multicenter
Vasopressin and Septic Shock Trial (VASST) [14].
The combined replication cohort of 738 patients had
141 patients treated with DAA. Baseline characteristics of
DAA-treated and DAA-free patients showed significant
differences: DAA-treated patients were younger and
sicker. Because these imbalances could confound mortality
assessments, matching of controls (up to three DAA-free
patients for every DAA-treated patient) was done and
achieved balance between groups (Table 1). This matching
strategy will be used in our current study as described
below.
As recommended by international guidelines for asso-
ciation studies [15], the replication cohort was used to
confirm individual SNP results. Two-SNP composite
improved response polymorphisms (IRPs), A and B,
were constructed. Patients were classified as IRP A+ or−
and IRP B+ or− if they had one of both of the respon-
sive genotype. The individual SNPs in each IRP were
associated with a differential DAA treatment effect in
the PROWESS study and replicated in the combined
replication cohort (unpublished).
The two SNPs comprising IRP A were chosen based
first on the alignment of direction and strength of their
signals by analyzing the interaction of SNP and treatment
effect on mortality in both the PROWESS study and the
replication cohort. Secondly, these two SNPs were chosen
based on the known biological plausibility linking these
SNPs to underlying pathways of sepsis or pathways that
could affect the mechanisms of action of DAA. The two
SNPs comprising IRP A are RYR2 (ryanodine receptor 2
gene) rs684923 on chromosome 1 and ACIN1 (apoptotic
chromatin condensation inducer 1 gene) rs3751501 on
chromosome 14. The SNP of RYR2 could act to enhance
efficacy of activated protein C on protection of endothelial
permeability via its effects on endothelial protein C recep-
tor and sphingosine-1-phosphate receptor 1 [16]. Phos-
phorylation of a residue (S422) inACIN1 (Acinus-S variant)
by AKT (prosurvival kinase), completely inhibits cleavage
of Acinus-S by caspase-3, abrogating the formation of frag-
ment p17 which is essential for chromatin condensation
during apoptosis [17]. As a result, phosphorylation of S422
by AKT is reduced by the lack of phosphorylation in
amino acid residue S573. It is conceivable that lack of
phosphorylation in S478 due to 478 F mutation and the
change of polarity caused by the change from a polar
amino acid (S) to a nonpolar amino acid (F) would greatly
impact Acinus-S protein conformation and probably affect
the likelihood of S422 phosphorylation by AKT. If this
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were the case, the genetic variants rs3751501 (AA|AG),
associated with increased ARR (absolute risk reduction)
and coding for amino acid 478 F in ACIN1, would ren-
der ACIN1 constitutively nonphosphorylated at residue
478 F and hence constitutively nonphosphorylated at
S422, leading to AKT-independent regulation of chroma-
tin condensation by Acinus-S during apoptosis, because
nonphosphorylated acinus-S would be constitutively cleav-
able by caspase-3. In such a situation, cleavage of Acinus-
Sby caspase-3 would be more sensitive to inhibitors of
caspase-3, for example, inhibition of caspase-3 by rhAPC,
which would be consistent with the genotype (rs3751501)
by treatment interaction seen in our studies.
Two SNPs comprising IRP B were chosen based solely
on the strength of their signals in PROWESS and in the
replication cohort, without regard to biological plausibil-
ity. These two SNPs are SPATA7 (spermatogenesis asso-
ciated 7 gene) rs3179969 on chromosome 14 and FLI1
(Friend leukemia virus integration 1 gene) rs640098 on
chromosome 11.
The ARR in mortality by IRP status in the combined
replication cohort is shown in Figure 1. The ARR was
19.7% for IRP A+patients (95% confidence interval (CI)
2.2–37.1%), whereas for the IRP A−patients the ARR was
−8.9% (95% CI −22.6 to 4.9%). The SNP-by-treatment
interaction P value was 0.018 unadjusted and 0.066
adjusted for matching covariates. The proportion of
patients who were IRP A+was 33.7% (140/415) in the rep-
lication cohort. The ARR was 21.2% for IRP B+patients
(95% CI 3.2–39.2%), whereas for the IRP B−patients the
ARR was −5% (95% CI −18.2 to 8.2%). The SNP-by-
treatment interaction P value was 0.04 unadjusted and
0.069 adjusted for matching covariates. The proportion of
Figure 1 ARR was 19.7% for IRP A+patients (95% CI 2.2–37.1%)
and −8.9% for IRP A−patients (95% CI −22.6 to 4.9%). The SNP-
by-treatment interaction P value was 0.018 unadjusted and 0.066
adjusted for matching covariates. The proportion of patients who
were IRP A +was 33.7% (140/415) in the replication cohort. The ARR
was 21.2% for IRP B + patients (95% CI 3.2–39.2%) and −5% for IRP
B− patients (95% CI −18.2 to 8.2%). The SNP-by-treatment
interaction P value was 0.04 unadjusted and 0.069 adjusted for
matching covariates. The proportion of patients who were IRP
B +was 26.1% (107/410) in the replication cohort.
Table 1 Baseline characteristics of replication cohorts before and after matching
Before matching After matching
Demographic or disease
characteristic
VASST cohort SPH cohort VASST and SPH combined
DrotAA
(n= 103)
Control
(n = 370)
P value DrotAA
(n = 38)
Control
(n = 227)
P value DrotAA
(n = 130)
Control a
(n = 286)
P
value
Age
Mean± SD 57.6 ± 15.6 62 ± 15.4 0.009 54.6 ±20.1 61 ± 14.9 0.072 58.4 ± 15.4 58.7 ± 15.3 0.886
Women (percentage of
patients)
35.9% 41.4% 0.32 44.7% 33.5% 0.178 40% 36.8% 0.596
APACHE II score
Mean± SD 27± 7.4 0.253 25.7 ± 6.4 22.9 ± 7.2 0.02 27.1 ± 5.8 27 ± 5.9 0.862
Medical (percentage of
patients)
85.4% 76.5% 0.051 89.5% 83.3% 0.332 86.2% 79.4% 0.106
Organ failure (percentage of
patients)
Cardiovascular 100% 100% 1 84.2% 82.4% 0.783 95.4% 96.2% 0.418
Respiratory 85.4% 85.4% 0.994 94.7% 93% 0.686 86.9% 86% 0.71
Renal 61.2% 46.2% 0.007 47.4% 46.3% 0.899 59.2% 55.5% 0.172
Hematologic 23.3% 19.5% 0.391 13.2% 13.7% 0.934 19.2% 15.1% 0.292
Ventilation (percentage of
patients)
98.1% 93.5% 0.073 100% 89.4% 0.036 99.2% 99.2% 1
Caucasian (percentage of
patients)
80.6% 83.2% 0.528 NA NA NA NA
aWeighted values for control group.
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patients who were IRP B+was 26.1% (107/410) in the
replication cohort.
The SGX301 study
Hypothesis and overall design
The study hypothesis is that IRP A and/or IRP B predict
a differential DAA treatment effect in patients with se-
vere sepsis and high risk of death. The design of this
international, multicenter, retrospective, controlled, out-
come-blinded, genotype-blinded, matched-patients study
is depicted in Figure 2. Retrospectively collected DNA
and clinical data will be analyzed to validate the prespe-
cified IRPs. Some of the cohorts are drawn from patient
registries and others are from clinical trials where the
primary hypothesis was not related to DAA. Prospective
aspects of this study are the genotyping of patients with
regard to the IRPs and the statistical testing of the pre-
specified hypothesis regarding the interaction of IRP
genotypes and DAA treatment on mortality. Eight aca-
demic centers will contribute data and DNA from ten
cohorts (5 EU, 4 USA, 1 Canada).
For each IRP, individual patients will be considered to be
biomarker positive if they have the responsive genotype
for either of the SNPs or for both of the SNPs in the IRP.
Ethics
All cohorts included in this study have complied with
local requirements with respect to requiring written,
informed consent and ethics committee oversight.
Original Cohort Databases 
Matching of Treated to 
Controls 
 Treated and Matched 
Controls Locked Together 
Final Dataset 
Non-INDICATED 
Population  
Final Dataset 
Severe Sepsis Population  
Genotypic and Outcomes 
data added 
Non-INDICATED 
Population (severe sepsis 
but not high risk of death) 
DATA TRANSFER #1: All Variables for Eligibility and Matching 
1 2 3 4 5 6 7 8 9 10 
Eligible Patients 
Severe Sepsis Population
INDICATED Population 
(severe sepsis and high risk 
of death) 
Matching of Treated to 
Controls 
DNA transferred to lab; 
genotyping conducted, 
blinded to treatment group 
and other data
Genotypic data sent from 
lab via each center 
Outcomes data 
 Treated and Matched 
Controls Locked Together 
Final Dataset 
INDICATED Population  
Genotypic and Outcomes 
data added 
DATA TRANSFER #2: 
Genotypic and Outcomes 
Data 
Figure 2 In data transfer #1, data from each patient in each of the ten cohorts are submitted and patients are considered for eligibility
criteria. Then, patients are segregated into the non-INDICATED (do not meet criteria for high risk of death as per FDA and EU approvals for DAA)
and INDICATED (fulfill FDA or EU approvals for DAA) populations (see text for details). Then, DAA-treated patients are matched with DAA-free
patients (controls). Subsequently, the matched sets are locked together. Then, the genotype and outcomes data are transferred (data transfer #2
described below) for each patient thereby creating a final dataset of non-INDICATED and INDICATED populations. Finally, the non-INDICATED and
INDICATED datasets are merged to create the final dataset of the severe sepsis (SEVSEP) population. In parallel with the matching process, each
center sends DNA for genotyping to the laboratory and genotyping is done while blinded to treatment group and outcome. The genotype data
and outcome data are then sent via each center to the central dataset as data transfer #2.
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Study population and treatment groups
To be included in the current study, patients must meet
eligibility criteria for the INDICATED population and
subsequently, DAA-treated patients will be matched to
DAA-free patients. Eligibility criteria, consistent with the
approved use of DAA in the United States and the Euro-
pean Union, will be used to select the primary study
population (INDICATED) from among all patients en-
rolled in the ten contributing cohorts (Table 2). This
population with high risk of mortality reflects common
practice for current use of DAA [18-23]. A second study
population with severe sepsis (non-INDICATED) also
will be selected in which severe sepsis patients do not
necessarily meet the high risk of death criteria. This
population will include all patients who meet criteria 1,
2, 4, and 5 in Table 2 from the ten cohorts. The INDI-
CATED and non-INDICATED populations will be
merged to constitute the SEVSEP population (Figure 2).
Patients at increased risk of bleeding due to low plate-
let counts are contraindicated for DAA use and will be
excluded from the INDICATED population. An add-
itional requirement for all patients will be that they had
to have been treated for severe sepsis either after DAA
was made available in their hospital (if known) or after
the drug was approved in their country or within 24
months before that date. This will ensure that control
(non-DAA–treated) patients are from a similar time
period as the DAA-treated patients.
No patients will be prospectively treated under this
protocol. DAA-treated patients were given DAA in ac-
cordance with local regulatory approvals and clinical
practice in each center. The recommended regimen for
DAA is 24 μg/kg per hour continuous intravenous infu-
sions for 96 hours. The timing of DAA administration
relative to day 1 (the day of diagnosis of severe sepsis
with high risk of death) will be collected when available.
Matching of DAA-treated to control patients
In practice, DAA is typically given to younger patients
with greater disease severity. Therefore, a well-matched
control group is critical to the validity of this nonrando-
mized study. Therefore, our study design incorporates
an overall matching strategy. First, to control for differ-
ences in standard of care among centers and over time,
DAA-treated patients will be matched to controls
(DAA-free patients) enrolled within 2 years in the same
cohort. After eligibility is met, control patients will be
selected to match the DAA-treated patients using a
computerized optimal matching algorithm matching base-
line demographic and disease characteristics that have
been identified a priori as likely influencing the decision
to give DAA or the probability of death. The number of
matched control patients for each DAA-treated patient
will be variable (one to three). This strategy increases the
precision in the estimation of the differences between
groups [24,25].
The matching strategy will combine minimum-distance
matching with the use of “calipers” that force the matches
for selected variables to fall within specified tolerances. In-
dividual variables will be used to compute a multivariate
distance (Mahalanobis distance). A propensity score that
is the estimated probability that a patient would have
received DAA given their key baseline characteristics will
be calculated. Rosenbaum and Rubin suggested that to ob-
tain covariate balance, an approach combining both the
propensity score and covariate matching is superior to the
use of either strategy alone [26]. The intended clinical
variables for the calculation of the Mahalanobis distance
and the reasons these variables were chosen (based on lit-
erature review and discussions with coinvestigators) are in
Table 3.
Table 2 Eligibility criteria for INDICATED population
Eligibility criteria consistent with the approved use of DAA in the
USA and the EU will define the INDICATED population as follows:
1 Men or women age 18 years or older
2 Must have severe sepsis (must meet a, b, and c below)
a) Suspected or proven infection
b) Systemic inflammatory response syndrome (SIRS) (must meet 2 of 4
criteria)
i) Temperature <36°C or >38°C
ii) Heart rate >90 beats/minute
iii) Respiratory rate >20 breaths/minute or PaC02 <32 mm Hg or on
mechanical ventilation
iv) White blood cell count <4,000/mm3 or >12,000/mm3
a) At least one organ dysfunction due to sepsis based on definitions
of clinically significant organ dysfunction.
i) Cardiovascular dysfunction [must meet one of (1), (2), or (3) below]:
(1) systolic blood pressure ≤90 mmHg and pH ≤7.3
(2) mean arterial pressure ≤70 mmHg and pH ≤7.3
(3) reported use of a vasopressor alone is sufficient evidence of shock
i) Pulmonary dysfunction: PaO2/FiO2 ≤300 mm Hg
ii) Central Nervous System dysfunction: Glasgow Coma Score ≤12
iii) Coagulation dysfunction: platelets ≤80,000/mm3
iv) Renal dysfunction: creatinine ≥2.0 mg/dL
v) Hepatic dysfunction: bilirubin≥ 2.0 mg/dL
1) High risk of death (one of a, b, or c below)
a) APACHE II ≥25
b) SAPS II ≥54
c) Multiple organ dysfunction – two or more clinically significant
organ dysfunctions (as defined above), which have occurred within
2 days of each other
2) Platelet counts ≥30,000/mm3
3) DAA status known
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The propensity score will be estimated using a logistic
regression model for treatment group using the matching
variables included in the calculation of Mahalanobis dis-
tances across all centers, plus a categorical variable for cen-
ter. We will test for interaction between age and APACHE
II or SAPS II scores and for interactions between age and
each of the four organ dysfunctions (cardiovascular, re-
spiratory, hematologic, and renal). If individual interactions
are significant at the 0.05 level, then these interaction
terms will be included in the propensity score model.
Calipers will be applied to selected key variables to en-
sure close matches. For age, a maximum 5-year differ-
ence was chosen based on clinical judgment of what
seems “close” and with consideration of how age was
handled in the APACHE II scoring system, which
assigned age points based on 10-year intervals [34].
Thus, the 5-year caliper is tighter than the intervals used
for calculating APACHE II scores.
For APACHE II scores, we expect scores to be pre-
dominantly in the range from 20–40; patients must be
within 2 points of each other. A 2-point difference in
APACHE II scores in this range would give a difference
in predicted mortality of approximately 7% at the low
end and 1% at the high end. In the original APACHE II
publication [34], a 5-point difference in APACHE II
scores was associated with a statistically significant dif-
ference in mortality risk. Therefore the two-point caliper
for APACHE II is tighter than the difference that was
statistically significant. For SAPS II, a four-point caliper
will be applied to achieve comparability with the two-
point caliper for APACHE II score [35].
The propensity score caliper will be set at the value that
represents 0.6 standard deviations (of the average propen-
sity score). This will define subgroups of approximately
20% of the sample within which a match must be made.
Cochran and Rubin found that this leads to excellent bias
reduction [37-39].
No imputation of missing data will be done to satisfy
eligibility criteria. To support selection of matched
patients (once deemed eligible for study), missing data
for up to two matching variables will be allowed to be
imputed for an individual patient. Missing data will be
imputed using available data from that same center if for
any matching variable, the proportion of missing values
per center is <30% for the INDICATED population; if
higher, imputation will not be done. No missing data
imputations are allowed for age (an eligibility criterion)
and for APACHE II or SAPS II scores due to their
complexity.
A clinical research organization, Syreon Corporation,
will conduct the study. A two-phase transfer of data
from each center will be implemented to ensure that the
selection of matched control patients is implemented in
a blinded and unbiased manner. Data transfer 1 will
Table 3 Rationale for selected Mahalanobis distance variables
Baseline
characteristic
(variable)
Associated with
mortality risk
only
Associated with DAA
treatment selection and
mortality risk
Comments
Age √ Increased age is associated with increased mortality [3]. Age is a variable in
APACHE II [19] and SAPS II [26]; also known that DAA typically given to
younger patients [18-23]
APACHE II or
SAPS II
√ Both are proven predictive mortality scores; DAA typically given to patients
with higher scores [18-23]
Cardiovascular
organ
dysfunction
√ Mortality is higher in patients with septic shock versus sepsis without
shock; DAA believed to be particularly effective in patients with shock [27]
Respiratory
organ
dysfunction
√ Respiratory dysfunction increases mortality [28,29]
Renal organ
dysfunction
√ Renal dysfunction increases mortality [30,31]
Hematologic
organ
dysfunction
√ Hematologic dysfunction increases mortality [32,33]; DAA is particularly
effective in patients with coagulopathy disorders (low platelets) [27]
Use of
mechanical
ventilation
√ Need for mechanical ventilation increases mortality [28,29]
Medical or
surgical status
√ Type of admission is a variable in APACHE II and SAPS II [34,35]; recent
surgery is a relative contraindication for DAA due to increased bleeding risk
[7]
Site of primary
infection
√ Predicted mortality varies with site of primary infection, but this is mostly a
DAA selection bias variable; DAA may be particularly helpful when lung is
source of primary infection [36]
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include all variables needed to confirm eligibility and to
conduct the matching. Once the matching has been
completed, the matched sets of treated and control
patients will be “locked” together. Then data transfer 2
(outcomes and genotypic data) will be sent to Syreon.
Genotyping
Most centers will have already extracted DNA using stand-
ard techniques. Genotyping for the IRP SNPs will be done
using a validated TaqmanW-based analytical method, and
the laboratory will be blinded to treatment and outcome.
The plate layout of DNA samples for genotyping will be
randomized to avoid systematic bias introduced from la-
boratory method conditions. Specific DAA-treated patients
and their matched controls will be assigned to the same
plate to ensure the tightest control of external factors
within each set of matched patients. A panel of 93 Ancestry
Informative Marker (AIM) SNPs will be genotyped using
the Illumina GoldenGateW analytical method [38]. This
method for ancestry assignments (using the STRUCTURE
software package) has been shown to adequately identify
patients of European, African, and Asian ancestry [40,41],
the relevant ancestral groups for this study.
Statistical analysis
The target sample size is >700 DAA-treated patients in
the INDICATED population. If 750 DAA-treated
patients were enrolled and approximately 1,500 matched
control patients identified, this trial would have adequate
power when testing two hypotheses, IRP A and IRP B,
corrected for multiplicity testing. The study would have
approximately 90% power to detect a treatment-by-IRP
interaction based on an absolute reduction in mortality
of 15% in the DAA-treated group compared with the
control group in IRP + patients and with 1% to 2% differ-
ence in mortality between the treated and control
groups in the IRP− patients.
The primary analysis will be conducted using the
Matched-INDICATED population to compare the effect of
treatment in the IRP+ and IRP- groups by testing for the
effect of the interaction between IRP and DAA treatment
on the primary endpoint in a conditional logistic regres-
sion model, conditioning on the matching and incorporat-
ing the principal component scores from the AIM panel
data as covariates to control for potential population strati-
fication. The primary endpoint is in-hospital mortality
through day 28 (i.e., patients are followed until hospital
discharge or day 28, whichever comes first). Each of the
primary analyses, one for IRP A and one for IRP B, will be
conducted as a two-sided test with α=2.5% for an overall,
Bonferroni-corrected, type I error rate of 5%.
Estimates of the effect of treatment within each IRP sta-
tus subgroup also will be provided as odds ratios and their
95% CIs from the conditional logistic regression analysis.
For descriptive purposes, ARRs for each IRP status sub-
group and their 95% CIs based on weighted mortality esti-
mates also will be provided. Secondary analyses will include
matching variables as covariates in the regression model to
adjust for residual imbalances and possible confounding.
Additionally, an ethnicity subgroup analysis will investigate
the three-way interaction among ethnicity, treatment, and
IRP in a matched conditional logistic regression model.
For secondary endpoints, stratified Cox regression will
be used to estimate time to death in hospital (censored at
discharge) and time to death (censored at day 60). Condi-
tional logistic regression will be used to estimate the log-
odds of mortality as a function of IRP, treatment group,
interaction between IRP and treatment, conditioned on
the matched sets. Mechanical ventilator-free days, ICU-
free days, and hospital-free days (all through day 28) will
be analyzed using Poisson regression models. The same
analyses will be performed using the matched non-
INDICATED population.
Conclusions
A design-based approach matching DAA-free controls
to DAA-treated patients in a multicenter study of
patients who have severe sepsis and high risk of death
decreases lack of balance between groups for variables
associated with risk of death and response to DAA treat-
ment. The matched control group tightens control of
key variables associated with mortality and DAA treat-
ment selection. This design-based strategy optimizes dir-
ect comparison of the control to the DAA-treated group
for mortality by genotype. The matching and genotyping
will be done blinded to outcomes. The sample size and
power are adequate (>700 DAA-treated patients). The
matched control patients will be selected from approxi-
mately 18,000 potential controls. This large ratio of
DAA-free to DAA-treated patients assures good match-
ing. Finally, the individual SNPs of the primary hypoth-
esis IRPs were selected based on a GWAS in the pivotal
PROWESS trial and alignment of strength and direction
of signal in a replication cohort.
Because DAA use has been relatively low in the study
cohorts, this type of matched-patients study can be con-
ducted. If DAA were administered to most eligible patients,
it would be difficult to find appropriate DAA-free patients
to use as matched controls. DAA was typically used in less
than 10% of the indicated patients across the cohorts.
To validate a genomic biomarker that can identify a
subgroup of patients who would have an enriched DAA
treatment effect, our goal is to find a prescriptive gen-
omic biomarker that can guide the decision to treat with
DAA. Such a biomarker would provide a strong ration-
ale for reconsidering the use of DAA in a selected popu-
lation of patients with severe sepsis. Moreover, this
study will provide a unique model for future
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investigations that seek to identify subpopulations who
respond to sepsis therapies.
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